First dead vaccine: approval for Valneva in the EU possible in early 2022

by time news

Positive phase III results: Valneva is submitting vaccine for approval in Great Britain, which could come there later this year. However, the pharmacologist at MedUni Vienna puts the results into perspective.

Text The Austro-French vaccine manufacturer Valneva announced encouraging results of its phase III study of the Covid vaccine VLA2001 carried out in Great Britain on Monday. On average, the vaccine candidate led to the formation of more antibodies against the SARS-CoV-2 virus than was the case with the AstraZeneca vaccine. VLA2001 has also shown itself to be “generally well tolerated”, according to a broadcast.

With its Covid-19 vaccine, Valneva is pursuing the dead vaccine approach that has been tried and tested for decades: The entire killed virus is presented to the body. Consequently …

Select the offer and read on

Read all articles.

  • Exclusive SN Plus content from renowned SN editors
  • The digital newspaper as an e-paper in the SN app every day
  • Automatically ends

The first 3 months for only 0.99 euros per month.

Are you already a digital subscriber?

Your 30-day trial has expired

The first 3 months for only 0.99 euros per month.

  • Exclusive SN Plus content from renowned SN editors
  • The digital newspaper as an e-paper in the SN app every day
  • Cancel anytime after 3 months

* Monthly price after 3 months: from € 4.90

Accessed on October 18, 2021 at 02:17 am on https://www.sn.at/panorama/wissen/erster-totimpfstoff-zulassung-fuer-valneva-in-der-eu-anfang-2022-moeglich-111063358

READ Also:  Rush to vaccination, boom in bookings. Only 5% are against it

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.